Citations |
1.Barok, M., Isola, J., Palyi-Krekk, Z., Nagy, P., Juhasz, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., and Szollosi, J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther, 6: 2065-2072, 2007. 2. McCluskey AJ, et al. Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen. Mol Oncol., Jun;7(3):440-51, 2013 PMID: 23290417 3. Andrew J, et al. Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol Cancer Ther. Oct;12(10):2273-81, 2013 PMID: 23945077 4.Bhinder B, Shum D, Li M, Ibanez G, Vlassov AV, Magdaleno S, Djaballah H. Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens. PLoS One. 2014 Jul 2;9(7):e100676. PMID: 24987961 5.Yeh ES, Abt MA, Hill EG. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. Breast Cancer Res Treat. 2015 Jan;149(1):91-98. PMID: 25515931 6.Colombo M, Fiandra L, Alessio G, Mazzucchelli S, Nebuloni M, De Palma C, Kantner K, Pelaz B, Rotem R, Corsi F, Parak WJ, Prosperi D. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat Commun. 2016 Dec 19;7:13818. doi: 10.1038/ncomms13818. PMID: 27991503 7.Yeh ES, Williams CJ, Williams CB, Bonilla IV, Klauber-DeMore N, Phillips SL. Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration. Oncotarget. 2017 Nov 25;8(65):109358-109369. PMID: 29312613 |
Description |
Disease: Breast carcinoma Origin: Established from pleural effusions of a breast cancer patient (grade 3 invasive, T2N1M0) Species:Homo sapiens Tissue:Breast, mammary gland Morphology:Epithelial Properties:Adherent Cytogenic data:Human flat-moded highly rearranged hyperdiploid karyotype with 6% polyploidy - 46-56< 2n> XX, +1, +2, +2, +3, +5, +6, +7, +12, -13, -14, -15, -15, -16, -18, +17, +5mar, add(X)(p22.1), add(1)(q11), del(1)(q32.2), der(1)add(1)(p21)add(1)(q22), der(1)t(1; 6)(p11; q1?1)t(6; 5)(q25; ?p13), add(2)(q11)x2, t(2; 3)(q10; p10)add(2)(q25-31), add(3)(p11), der(4)t(?3; 4)(?q24; p11), add(5)(q15), der(5)add(5)(p15.3)del(5)(q22), der(5)t(5; 8)(p11; p11), add(6)(p11)add(6)(q23), der(7)t(1; 7)(p13; q21), der(7)t(7; ?12)(p11; p11), add(8)(p11), i(8q) add(9)(p11), der(9)add(9)(p11)add(9)(q23), add(11)(p13), der(11)dup(11)(p11p15)add(11)(p15), der(11)t(1; 11)(q24; p12), add(12)(q21), der(12; ?15)(p11; q11), add(17)(p11), add(17)(p13), der(17)add(17)(p11)add(17)(q21) Patient:Female, 62 yrs of age Medium:AddexBio-formulated DMEM (C0003-01) + 10% FBS Subculture:1:2 to 1:6 (80-90%); using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin - DNA Profile (STR): Amelogenin: X, X CSF1PO: 12, 13 D13S317: 8, 13 D16S539: 11, 11 D5S818: 12, 13, 14 D7S820: 12, 12 THO1: 7, 7 TPOX: 8, 8 vWA: 18, 18 Citation Format: If use of this culture results in a scientific publication, it should be cited in the publication as: JIMT-1 (AddexBio C0006005) Mutations in JIMT-1 Cells Related cells by Organ: 4T1 AU-565 BT-20 BT-474 BT-483 BT-549 JIMT-1 MCF-7 SK-BR-3 T47D ZR-75-1 |